{"ok":true,"entity":{"id":"tempus-ai","name":"Tempus AI","entityType":"company","officialName":"Tempus AI, Inc.","canonicalName":"Tempus AI","displayName":"Tempus AI","category":"AI精密医療・ゲノム診断企業","shortDescription":"Tempus AI, Inc.は決算発表の日付地がシカゴのNasdaq上場企業（ティッカーTEM）で、AIを活用した精密医療を掲げ、診断（Diagnostics）とデータ・アプリケーション（Data and Applications）の二つの事業を持つ。2026年第2四半期の売上高は3億8,250万米ドルで前年同期比22%増となり、2026年7月20日にPersonalisの買収で最終契約を結んだが、同社は完了を2026年第4四半期後半または2027年初頭の見込みとしている。","primaryCluster":"digital-health","parentEntity":null,"verificationStatus":"draft","website":"https://www.tempus.com/","updatedAt":"2026-10-13T05:13:13.513Z","secondaryClusters":[],"alias":["Tempus","Tempus AI, Inc."],"searchKeywords":["Tempus AI","テンパス","TEM","精密医療","ゲノム診断 AI","腫瘍 基盤モデル","Personalis買収","AstraZeneca Pathos","precision medicine AI","Tempus Chicago"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}